Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study DOI Creative Commons

Xichao Wang,

Xinyuan Song, Na Sun

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 26, 2025

Background Ripertamab has been used in an off-label manner for treating primary membranous nephropathy (PMN) real-world settings China, despite limited evidence supporting the efficacy of this drug. This multicenter, retrospective study is first to assess effectiveness and safety ripertamab PMN a Chinese clinical setting. Methods Adult patients with who were treated at least one course alone included study. Patients categorized into two groups based on their prior treatment PMN: initial therapy group non-initial group. The outcome was occurrence complete remission (CR) or partial (PR) 6 12 months. secondary outcomes time achieve remission, relapse rate incidence adverse events (AEs). Results Fifty-two ultimately analysis. Among these patients, 39 received as therapy, while 13 median follow-up duration 8.7 (4.7, 11.3) At months, 24/40 (60.0%) achieved 2/40 (5.0%) achieving CR 22/40 (55.0%) PR. 22 completed follow-up: 2 (9.1%) CR, 15 (68.2%) entire cohort 90.5 (32, 165) days four 52 (7.7%) relapsed. had higher months than [13/15 (86.7%) vs. 4/7 (57.1%)]. Additionally, more quickly [79.0 (36, 112) 165.0 (30, 313) days]. well tolerated, 9.6% (5/52) experiencing AEs; none AEs severe. Conclusion demonstrated good tolerability These findings support use therapeutic option suggest need further investigation its long-term efficacy.

Language: Английский

Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study DOI Creative Commons

Xichao Wang,

Xinyuan Song, Na Sun

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 26, 2025

Background Ripertamab has been used in an off-label manner for treating primary membranous nephropathy (PMN) real-world settings China, despite limited evidence supporting the efficacy of this drug. This multicenter, retrospective study is first to assess effectiveness and safety ripertamab PMN a Chinese clinical setting. Methods Adult patients with who were treated at least one course alone included study. Patients categorized into two groups based on their prior treatment PMN: initial therapy group non-initial group. The outcome was occurrence complete remission (CR) or partial (PR) 6 12 months. secondary outcomes time achieve remission, relapse rate incidence adverse events (AEs). Results Fifty-two ultimately analysis. Among these patients, 39 received as therapy, while 13 median follow-up duration 8.7 (4.7, 11.3) At months, 24/40 (60.0%) achieved 2/40 (5.0%) achieving CR 22/40 (55.0%) PR. 22 completed follow-up: 2 (9.1%) CR, 15 (68.2%) entire cohort 90.5 (32, 165) days four 52 (7.7%) relapsed. had higher months than [13/15 (86.7%) vs. 4/7 (57.1%)]. Additionally, more quickly [79.0 (36, 112) 165.0 (30, 313) days]. well tolerated, 9.6% (5/52) experiencing AEs; none AEs severe. Conclusion demonstrated good tolerability These findings support use therapeutic option suggest need further investigation its long-term efficacy.

Language: Английский

Citations

0